Negative correlation between placental growth factor and endocan-1 in women with preeclampsia / Correlação negativa entre fator de crescimento placentário e endocan-1 emmulheres com pré-eclâmpsia

Abstract Objective To analyze endocan-1, a biomarker of vascular endothelial related pathologies, and the placental growth factor (PlGF), an angiogenic factor and a placental dysfunction marker in patients with preeclampsia (PE). Methods Case-control study conducted at Hospital São Lucas, in the city of Porto Alegre, Brazil. Endocan-1 and PlGF levels were quantified in the maternal plasma using the MagPlexTH-C microsphere system (MAGPIX System, Luminex, Austin, Texas, US) and evaluated through analysis of covariance (ANCOVA) and adjusted by body mass index (BMI), gestational age and maternal age. To estimate the difference between the groups, the mean ratio (MR) and the 95% confidence interval (95%CI) were calculated. The Pearson correlation test was used to establish any association between endocan-1 and PlGF levels. The null hypothesis was rejected when p < 0.05. Results The group of patients was composed by normotensive (n = 67) patients and patients with PE (n = 50). A negative correlation between endocan-1 and the PlGF was noted in the entire normotensive group (linear correlation coefficient [r] = -0.605; p < 0.001), as well as in the PE group (r = -0.545; p < 0.001). Conclusion Endocan-1 levels are increased in patients with PE, and are inversely correlated with PlGF levels. We suggest that it is important to analyze angiogenic and proinflammatory molecules concomitantly in women with PE to better understand the pathophysiology of the disease. Both molecules are strong candidates for PE biomarkers, and future studies will examine any mechanisms connecting these factors in PE.

Resumo Objetivo Analisar o endocan-1, umbiomarcador de patologias vasculares endoteliais, e o fator de crescimento placentário (FCPl), um fator angiogênico, marcador de disfunção placentária em pacientes com pré-eclâmpsia (PE). Métodos Estudo de caso-controle realizado no Hospital São Lucas, em Porto Alegre. Os níveis de endocan-1 e FCPl foram quantificados no plasma materno usando o sistema de microesferas MagPlexTH-C (MAGPIX System, Luminex, Austin, Texas, US) e analisados por análise de covariância (ANCOVA) e ajustados por índice de massa corporal (IMC), idade gestacional e idade materna. Para calcular a diferença entre os grupos, utilizou-se a razão dasmédias (RM) e o intervalo de confiança de 95% (IC95%). O teste de correlação de Pearson foi utilizado para estabelecer a associação entre os níveis de endocan-1 e FCPl. A hipótese nula foi rejeitada quando p < 0,05. Resultados O grupo de pacientes foi composto por pacientes normotensas (n = 67) e pacientes com PE (n = 50). Uma correlação negativa entre o endocan-1 e o FCPl foi observada emtodo o grupo de pacientes normotensas (coeficiente de correlação linear [r] = -0,605; p < 0,001), bem como no grupo com PE (r = -0,545; p < 0,001). Conclusão Os níveis de endocan-1 estão aumentados em pacientes com PE e inversamente correlacionados com os níveis de FCPl. Sugerimos a importância de analisar moléculas angiogênicas e pró-inflamatórias concomitantemente em mulheres com PE para compreender melhor a fisiopatologia da doença. Ambas as moléculas são fortes candidatos a serem considerados biomarcadores de PE, e trabalhos futuros poderão avaliar quaisquer mecanismos que liguem esses fatores na PE.

Cartilage proteoglycan aggrecan: potential as serum marker of cartilage destruction in juvenile rheumatoid arthritis

To investigate whether aggrecan is to be considered a useful marker and a predictor of joint cartilage destruction in juvenile rheumatoid arthritis patients [JRA]. Aggrecan was quantified with ELISA in sera from 31 children suffering of JRA and synovial fluid [SF] of 10 of them. Patients were evaluated at baseline and 3 months later. a] Clinically with the overall articular severity score. b]Laboratory tests including ESR, CRP, total leucocytic and platelet counts, hemoglobin and rheumatoid factor. c] Radiologically with modified Larsen, malalignment and vanRossum's scores. Radiographs were also repeated after one year. A group of 15 normal healthy children and another of 10 children with arthritis due to other collagen vascular diseases were studied for comparison. Baseline serum aggrecan was significantly higher in JRA patients as compared to controls and to patients with other collagen vascular diseases with 93% sensitivity and 100% specificity at a cut off level of 18.6 ng/ml [control mean + 3 SD]. On reevaluation, a significant drop of serum aggrecan from baseline values was noticed [p < 0.01] that coincided with a significant drop in clinical and laboratory indices of active inflammation although their levels correlated poorly. Serum aggrecan levels were insignificantly different from those of SF and both correlated significantly with SF protein concentration. Lower levels of serum aggrecan were observed in patients with radiographic evidence of joint destruction and in those with evidence of deterioration one year later. Serum aggrecan can help to assess the extent of cartilage destruction and is useful as a prognostic tool to predict joint damage in patients with JRA

An anorectic proteoglycan of membrane origin.

The endogenous substance(s) involved in the regulation of food intake has been isolated from serum, urine and feces. In the present study, a similar type of anorexigenic proteoglycan was isolated from human rat erythrocyte membranes and rat liver membranes. Membranes were suspended in 2.0% deoxycholate and allowed to stand at 25 degrees C for 30 min. The suspension was treated with 5% TCA, supernatant was collected, dialyzed and concentrated. TCA-soluble proteins were fractionated on Sephadex G-150. The active second peak fractions were further purified on DEAE-Sephadex A-25. Biologically active substance reduced the appetite in rats significantly when given intraperitoneally. The proteoglycan (50 kDa) consisted of 70-85% carbohydrate. Similar properties of plasma and membrane anorectic substance further indicated its membrane origin. We believe that this anorectic proteoglycan is anchored to cell membranes and released into the blood circulation to regulate the food intake.